NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on March 10, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time.
Conference Call & Webcast Details
| Date: | Monday, March 10th |
| Time: | 4:30 p.m. Eastern time |
| Toll-Free Dial-In: | 800-225-9448 |
| International Dial-In: | 203-518-9708 |
| Conference ID: | LIFEMD |
| Live & Archived Webcast: | Link |
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Investor Contact
Marc Benathen, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Jessica Friedeman, Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$3.84 |
| Daily Volume: | 0 |
| Market Cap: | US$184.860M |
November 17, 2025 November 17, 2025 November 04, 2025 September 18, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load